In people with primary progressive multiple sclerosis (MS), a new study has found no difference in the amount of time before ...

An overhaul of the way Pharmac decides to fund drugs for people with chronic long term diseases is needed, say health ...

The FDA has approved a new injectable form of the multiple sclerosis drug ocrelizumab for use in adults with relapsing and progressive forms of the disease. Multiple sclerosis occurs when the body ...

The report explains that Pharmac’s current funding model is a cost utility analysis (CUA), which is a subset of cost effectiveness analysis. In this, Pharmac weighs up the direct healthcare costs and ...

Hacohen reported on a UK cohort of children with MS treated with ocrelizumab, with 66 patients having more than 12 months of follow-up. Of these, only four patients had relapses, and there was no ...

Other board members include Dr. Christian Dansereau, Perceiv AI co-founder and CEO, and Dr. César Laurent, co-founder and CTO ...

The U.S. Food and Drug Administration has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) as the first and only twice-a-year, 10-minute subcutaneous injection for people with ...

Chair of the Meningitis Foundation, Gerard Rushton says he fully supports MSNZ and its call for Pharmac to adopt a new funding evaluation model that considers more than just the direct healthcare ...

Oditrasertib, which blocks the inflammatory RIPK1 protein, earlier this year also failed a Phase II trial in amyotrophic ...

Furthest ahead in the pipeline is tolebrutinib, developed by Paris-based Sanofi to potentially treat SPMS, PPMS and relapsing forms of MS. The investigational agent is an oral central nervous system ...

Multiple sclerosis is a complex and challenging condition to manage, but a wide range of therapies offers hope for patients.

In addition, although not in the guidelines, it is thought that the anti-CD20 monoclonal antibodies, such as rituximab or ocrelizumab, may be safe as they are very long acting. Women can be dosed ...